Tag Archives: anti-angiogenic therapy

May, 2016

  • 16 May

    FDA Expands Approval of Eisai’s Lenvima in Kidney Cancer

    WOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA® (lenvatinib), the company’s multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an …